linjc16/ctgov huggingface dataset:
Evaluating the Accuracy of Microvessel Ultrasound Imaging for Detecting Extent of Disease in Patients With Angiosarcoma of the Skin

Study Overview
=================
Brief Summary
-----------------
This study evaluates the accuracy of a new ultrasound technology called microvessel imaging for detecting the extent of disease among patients with angiosarcoma of the skin. Microvessel ultrasound imaging uses high frequency waves to visualize vessels in the skin that are not easily seen using other imaging tests.

Detailed Description
-----------------
PRIMARY OBJECTIVE: I. To determine the accuracy of depicting extent of disease of cutaneous angiosarcoma before and after neoadjuvant treatment compared to clinical photographs, magnetic resonance imaging (MR) or positron emission tomography (PET)/computed tomography (CT) imaging and surgical pathology both on skin biopsies and surgical excision. OUTLINE: Patients undergo microvessel ultrasound imaging on study.

Official Title
-----------------
Microvessel Ultrasound Imaging of Cutaneous Angiosarcoma

Conditions
-----------------
Skin Angiosarcoma

Intervention / Treatment
-----------------
* Device: Ultrasound Microvessel Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Diagnosed with cutaneous angiosarcoma of the breast or scalp and scheduled for trimodality therapy Twenty one years of age or older Exclusion Criteria: Unwilling to consent to microvessel ultrasound imaging Younger than 21 years of age

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational (microvessel ultrasound imaging)<br>Patients undergo microvessel ultrasound imaging on study. | Device: Ultrasound Microvessel Imaging<br>* Undergo microvessel ultrasound imaging<br>* Other names: UMI;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of microvessel ultrasound imaging | Accuracy with respect to gold standard quantitative measures of disease extent and imaging-based measurements will be evaluated using Lin's concordance correlation coefficient along with 95% confidence intervals (CI's). These will be performed separately pre- and post-treatment. Pearson correlations and 95% CI's between imaging modality measurements will also be estimated to help guide future comparative analyses. Bland-Altman plots will also be generated to visualize agreement. | Through to study completion up to one year |
Continuous Glucose Monitoring in Peri-operative Period in Kidney Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
his study aims to utilize Continuous Glucose Monitoring (CGM) to observe glucose fluctuations in kidney transplant recipients and predict New-Onset Diabetes After Transplantation (NODAT) based on these patterns. Additionally, it seeks to investigate glucose variability resulting from medications and surgeries such as immunosuppressants and steroid regimens post-kidney transplantation. This prospective observational study anticipates identifying factors influencing blood glucose levels and contributing to future research on blood glucose management using CGM monitoring in kidney transplant patients.

Official Title
-----------------
Prospective Observational Study for Efficacy of Perioperative Serum Glucose Level Evaluated by Continuous Glucose Monitoring System in Kidney Transplantation Patients

Conditions
-----------------
New Onset Diabetes After Transplantation

Intervention / Treatment
-----------------
* Diagnostic Test: continuous glucose monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The study will target 100 kidney transplant patients who have provided consent, among those who underwent the procedure at Seoul National University Hospital after March 2021. Exclusion Criteria: multi-organ transplant history of previous kidney transplant less than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: continuous glucose monitoring|FreeStyle Libre Flash Glucose Monitoring System|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of NODAT | rate of new onset diabetes after transplantation | 6 months after kidney transplantation |
Predictive Factors for Survival in Aggressive Meningiomas

Study Overview
=================
Brief Summary
-----------------
The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.

Official Title
-----------------
Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma

Conditions
-----------------
Meningioma Atypical, Meningioma, Anaplastic Meningioma

Intervention / Treatment
-----------------
* Diagnostic Test: Biological biomarker assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient operated for atypical (grade 2) meningioma; or Patient operated for anaplastic (grade 3) meningioma; Timeframe for surgery, 1999-2019 Exclusion criteria 1) Patient lost at follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Biological biomarker assessment<br>FFPE tumor tissue will be processed with a number of molecular biology techniques | Diagnostic Test: Biological biomarker assessment<br>* IHC, PCR, NGS, methylome<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence-free survival (RFS) | Correlation from biomolecular data and RFS | 5 years on average | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) | Correlation from biomolecular data and OS | 5 years on average |
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy

Study Overview
=================
Brief Summary
-----------------
Diabetes nephropathy (DN) is one of the most serious microvascular complications of diabetes, and also an important cause of death and disability of diabetes patients. There is no specific clinical staging of type 2 diabetes nephropathy at home and abroad, and there is no comprehensive study to comprehensively describe the occurrence and development of type 2 diabetes nephropathy through sensitive biomarkers, microvascular disease imaging and functional detection, digital markers and other multi-dimensional diagnosis and evaluation methods. Therefore, our research aims to establish a long-term follow-up queue for the whole cycle of diabetes nephropathy, develop multi-dimensional diagnostic and progress digital markers for diabetes nephropathy, develop a multimodal non-invasive diagnostic model and a new clinical staging/typing, and create a multi-dimensional accurate diagnosis and treatment system for type 2 diabetes nephropathy combining traditional Chinese and western medicine.

Official Title
-----------------
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy

Conditions
-----------------
Diabetic Nephropathy Type 2, Diabetic Kidney Disease, Type 2 Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old, regardless of gender; Type 2 diabetes; Having a complete medical history and clinical data; If the patients with type 2 diabetes combined with CKD underwent renal biopsy, the pathological diagnosis should be clear; Patients voluntarily signs an informed consent form. Exclusion criteria: Incomplete medical history or clinical data; Patients with hereditary kidney disease; Combined urinary tract infection; Merge autoimmune system diseases; Patients with malignant tumor were expected to survive less than 6 months; Pregnancy and lactation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Type 2 diabetic nephropathy<br>The cohort will be divided into 2 or 3 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in estimated glomerular filtration rate (eGFR) from baseline | eGFR is calculated using the CKD-EPI formula, involving gender, age, and serum creatinine. | 24months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic Nephropathy Type 2, Diabetic Kidney Disease, Type 2 Diabetes, Diagnosis, Treatment
China Axial Length Study

Study Overview
=================
Brief Summary
-----------------
The primary objective of this multi-center, observational study is to establish the reference ranges of axial length in Chinese children and adolescents. 30,000 children aged 3-18 years were examined with cycloplegia to collect their ocular parameters and were all followed up for three years with annual visits.

Official Title
-----------------
Axial Length Study of Children and Adolescents in Ten Provinces of China

Conditions
-----------------
Axial Length, Children, China

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 3 to 18 years Have been lived in the research areas for at least one year, and will not move to other places in the following two years Parents or guardians sign an informed consent form, and children over 6 years old need oral consent to participate Exclusion Criteria: Mental diseases, unable to cooperate to complete the eye assessment Ophthalmic diseases, inability to cooperate to complete the inspection

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Myopes<br>To collect the ocular data among myopic children. | |
| Non-myopes<br>To collect the ocular data among non-myopic children. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Axial length | Axial length was examined by IOL Master | 2023-2025 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Axial length elongation | The elongation was the difference between two annual visits. | 2023-2025 |
The Effect Of Smartphone Addiction On Trunk Muscles Performance In Adolescents

Study Overview
=================
Brief Summary
-----------------
Statement of the problem: Does overuse of the smartphones affect trunk muscles performance in normal adolescents it will be assumed that There will be no affection of smartphone addiction on trunk muscles performance in normal adolescents

Detailed Description
-----------------
Subjects: - Sixty - six normal healthy adolescent from both genders will be recruited for the study from high school students and first year university students, they will be divided according to their smart phone addiction scale short version (SAS-SV) scores into two groups: Group (A): smartphone addicts (consists of 33 participants) Group (B): smartphone non- addicts (consists of 33 participants) Inclusion criteria Age ranges from 14 to 18 years Have Body Mass Index (BMI) = 5th percentile to less than the 85th percentile 2. Exclusion criteria Subjects will be excluded from the study if he/she has: visual or hearing defects overweight or obese neurological disorder marked musculoskeletal problem

Official Title
-----------------
The Effect Of Smartphone Addiction On Trunk Muscles Performance In Adolescents

Conditions
-----------------
Smartphone Addiction, Muscle Weakness Condition, Adolescents

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ranges from 14 to 18 years Have Body Mass Index (BMI) = 5th percentile to less than the 85th percentile Exclusion Criteria: Subjects will be excluded from the study if he/she has: visual or hearing defects overweight or obese neurological disorder marked musculoskeletal problem

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| smartphone addiction group<br>smartphone addiction will be assessed using smartphone addiction scale short version(SAS-SV) evaluation of trunk muscles performance using isokinetic dynamometer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluation of the trunk muscles performance | the isokinetic dynamometer will be used to assess the trunk muscles performance by using HUMAC CSMI isokinetic dynamometer | baseline only |
Specific Role of Nurse in a Mobile Palliative Care Team (EMSP): Real Autonomy or Utopia

Study Overview
=================
Brief Summary
-----------------
A bibliographic search carried out by the investigators demonstrated that there are few studies or data relating to the role and place of a State Registered Nurse (IDE) in a Mobile Palliative Care Team (EMSP) concerning the collection and the analysis of the needs expressed when formulating an evaluation request by the EMSP. The IDE collects, questions, analyzes needs and initiates an evaluation with the patient or, failing that, advises and/or redirects. This first necessary step before the overall evaluation led the investigators to question the autonomy of the IDE in an EMSP and to research what are the representations of an IDE in this role of collecting and analyzing needs. when making such a request? The aim of this research is to explore the professional practices of nurses within other PMSCs in order to analyze them and move towards improving patient care.

Official Title
-----------------
Specific Role of Nurse in a Mobile Palliative Care Team (EMSP): Real Autonomy or Utopia

Conditions
-----------------
Palliative Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: State-certified nurse working in EMSP with intra- and extra-hospital activity in a CHRU or CHU. Subject having given their consent for the reuse of their data for the purposes of this research Exclusion criteria: Subject having expressed opposition to participating in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Review of professional practices in Palliative Care | The study consisted of an inventory of professional practices of nurses within mobile palliative care teams | Study covers the period from February 9, 2023 to March 9, 2024 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Improving patients care, Nurse, Palliative Care
Prostate Diffusion Imaging With Distortion Correction

Study Overview
=================
Brief Summary
-----------------
There has been literature demonstrating the effectiveness of correcting these MRI images by using an additional measurement of the magnetic field, but the implied improvement in lesion detection in these common distorted regions in the prostate has yet to be shown. We propose that introducing this distortion correction would greatly improve the DWI images used for tumour detection. For this study we propose testing this hypothesis as a primary objective, and as a secondary objective including additional b-values to further refine the ADC value. The study involves adding one additional distortion correcting scan to the standard clinical study, adding approximately 2 minutes to the study.

Official Title
-----------------
Prostate Diffusion Imaging With Distortion Correction

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: MRI scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male Aged 18 and over No contraindication to MR scanning Smokers and non-smokers Patients who have had a complete scan on the 3T scan MRI at Norfolk and Norwich University Hospital and have gone on to have a biopsy at the Norfolk and Norwich University Hospital Exclusion Criteria: Previous diagnosis of prostate cancer, prostatic biopsy or treatment for prostate cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Imaging<br> | Diagnostic Test: MRI scan<br>* MRI scan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI image quality | To determine whether correcting for the distortion in MRI images caused by rectal gas improves the image quality and thus diagnostic ability in localising and detecting prostate cancer | 12 months |
Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

Study Overview
=================
Brief Summary
-----------------
This exploratory study is designed to compare safety and efficacy between a Tegoprazan dose-specific standard triple therapy and Lansoprazole standard triple therapy in H. pylori positive patients.

Detailed Description
-----------------
A Randomized, Double-Blind, Active-controlled, Multicenter, Therapeutic Exploratory Study to to Evaluate the Safety and Efficacy of a Standard Triple Therapy with Tegoprazan and Lansoprazole standard triple therapy in H. pylori Positive Patients, twice a day for 14 days.

Official Title
-----------------
A Randomized, Double-Blind, Active-controlled, Multi-center, Therapeutic Exploratory Study to Evaluate the Safety and Efficacy of a Standard Triple Therapy With Tegoprazan (by Dose) in H. Pylori Positive Patients

Conditions
-----------------
Helicobacter Pylori Infection

Intervention / Treatment
-----------------
* Drug: Tegoprazan 50 mg Triple Therapy
* Drug: Tegoprazan 100 mg Triple Therapy
* Drug: Lansoprazole Triple Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: H. pylori positive at screening Subjects who have upper gastrointestinal disease Exclusion Criteria: Having received prior therapy for eradication of H. pylori Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tegoprazan 50 mg<br>Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days | Drug: Tegoprazan 50 mg Triple Therapy<br>* Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days<br>|
| Experimental: Tegoprazan 100 mg<br>Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days | Drug: Tegoprazan 100 mg Triple Therapy<br>* Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days<br>|
| Active Comparator: Lansoprazole<br>Lansoprazolee/Clarithromycin/ Amoxicillin BID peroral, 14 days | Drug: Lansoprazole Triple Therapy<br>* Lansoprazole/Clarithromycin/ Amoxicillin BID peroral, 14 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| H. pylori eradication rate | Assess H. pylori eradication rate by UBT | 42 days |